TY - JOUR
T1 - Involvement of extracellular signal-regulated kinase 2 and stress- activated protein kinase/Jun N-terminal kinase activation by transforming growth factor β in the negative growth control of breast cancer cells
AU - Frey, Randall S.
AU - Mulder, Kathleen M.
PY - 1997
Y1 - 1997
N2 - Although transforming growth factor β (TGF-β) is known to be a potent growth inhibition of breast cancer cells (BCCs), the signaling mechanisms mediating TGF-β responses have not been defined. We have demonstrated previously that TGF-β can activate Ras and extracellular signal-regulated kinase (ERK) 1 in untransformed epithelial cells (K. M. Mulder and S. L. Morris, J. Biol. Chem., 267: 5029-5031, 1992; M. T. Hartsough and K. M. Mulder, J. Biol. Chem., 270: 7117-7124, 1995). We have also shown that TGF- β signaling is altered in epithelial cells when Ras activation is blocked (Hartsough et al., J. Biol. Chem., 271: 22368-22375). Here we demonstrate the ability of the TGF-β3 isoform to activate the signaling component ERK2 in TGF-β-sensitive BCCs but not in TGF-β-resistant cells. The ERK2 isoform was activated by 6-fold within 10 min of TGF-β3 addition to the TGF-β- sensitive BCC line Hs578T. Moreover, the IC50 for inhibition of DNA synthesis by TGF-β3 in this cell line correlated with the EC50 for TGF- β3 activation of ERK2. In contrast, TGF-β3 had little effect on either DNA synthesis or ERK2 activation in ZR-75 BCCs lacking the type-II TGF-β receptors (R(II)), or in ZR-75 BCCs stably transfected with R(II) yet still TGF-β resistant. In addition, our data demonstrate that TGF-β3 affected a sustained activation of the stress-activated protein kinase/Jun N-terminal kinase (SAPK/JNK) type of mitogen-activated protein kinase (MAPK); maximal induction levels were 2.5-fold above basal values and were attained at 30 min after TGF-β3 treatment. In contrast, TGF-β3 did not increase SAPK/JNK activity in the TGF-β-resistant ZR-75 R(II) BCCs. Our data provide the first evidence that TGF-β activation of ERK2 and SAPK/JNK is associated with negative growth control of BCCs. This is also the first demonstration that TGF-β can activate the SAPK/JNK type of MAPK and that the TGF-β3 isoform can regulate MAPK activity.
AB - Although transforming growth factor β (TGF-β) is known to be a potent growth inhibition of breast cancer cells (BCCs), the signaling mechanisms mediating TGF-β responses have not been defined. We have demonstrated previously that TGF-β can activate Ras and extracellular signal-regulated kinase (ERK) 1 in untransformed epithelial cells (K. M. Mulder and S. L. Morris, J. Biol. Chem., 267: 5029-5031, 1992; M. T. Hartsough and K. M. Mulder, J. Biol. Chem., 270: 7117-7124, 1995). We have also shown that TGF- β signaling is altered in epithelial cells when Ras activation is blocked (Hartsough et al., J. Biol. Chem., 271: 22368-22375). Here we demonstrate the ability of the TGF-β3 isoform to activate the signaling component ERK2 in TGF-β-sensitive BCCs but not in TGF-β-resistant cells. The ERK2 isoform was activated by 6-fold within 10 min of TGF-β3 addition to the TGF-β- sensitive BCC line Hs578T. Moreover, the IC50 for inhibition of DNA synthesis by TGF-β3 in this cell line correlated with the EC50 for TGF- β3 activation of ERK2. In contrast, TGF-β3 had little effect on either DNA synthesis or ERK2 activation in ZR-75 BCCs lacking the type-II TGF-β receptors (R(II)), or in ZR-75 BCCs stably transfected with R(II) yet still TGF-β resistant. In addition, our data demonstrate that TGF-β3 affected a sustained activation of the stress-activated protein kinase/Jun N-terminal kinase (SAPK/JNK) type of mitogen-activated protein kinase (MAPK); maximal induction levels were 2.5-fold above basal values and were attained at 30 min after TGF-β3 treatment. In contrast, TGF-β3 did not increase SAPK/JNK activity in the TGF-β-resistant ZR-75 R(II) BCCs. Our data provide the first evidence that TGF-β activation of ERK2 and SAPK/JNK is associated with negative growth control of BCCs. This is also the first demonstration that TGF-β can activate the SAPK/JNK type of MAPK and that the TGF-β3 isoform can regulate MAPK activity.
UR - http://www.scopus.com/inward/record.url?scp=0031059867&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031059867&partnerID=8YFLogxK
M3 - Article
C2 - 9044838
AN - SCOPUS:0031059867
SN - 0008-5472
VL - 57
SP - 628
EP - 633
JO - Cancer Research
JF - Cancer Research
IS - 4
ER -